Cancer
Malignant Thyroid Gland Neoplasm
CI-CAN-00003251Explore in graph →
Top-level176 active trials10 approved drugs63 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer
CI-CAN-00003251Explore in graph →
Clinical trials
790 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (65)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01013597 | Trial of LBH589 in Metastatic Thyroid Cancer | completed | Phase 2 | 13 | University of Wisconsin, MadisonOTHER | 1 | Nov 29, 2019 | clinicaltrials |
| NCT00654238 | Phase II Trial of Sorafenib (Nexavar) in Patients With Advanced Thyroid Cancer | completed | Phase 2 | 59 | University of PennsylvaniaOTHER | 1 | Nov 18, 2019 | clinicaltrials |
| NCT02084732 |
| Safety and Efficacy of Sorafenib in Patients With Advanced Thyroid Cancer: a Phase II Clinical Study |
| completed |
| Phase 2 |
| 35 |
| Instituto Nacional de Cancerologia, ColumbiaOTHER_GOV |
| 1 |
| Nov 13, 2019 |
| clinicaltrials |
| NCT02768753 | Comparison Between the Axillary Bilateral-breast Approach (ABBA) and Bilateral Axillo-breast Approach (BABA) for Robotic Thyroidectomy | completed | N/A | 60 | Jinan Military General HospitalOTHER | 1 | Sep 27, 2019 | clinicaltrials |
| NCT04072731 | SREBP1 as a Potential Biomarker Promotes Cell Proliferation and Invasion in Thyroid Cancer | completed | — | 140 | People's Hospital of Zhengzhou UniversityOTHER | 1 | Aug 28, 2019 | clinicaltrials |
| NCT00428220 | A Continuation Study Using Sunitinib Malate For Patients Leaving Treatment On A Previous Sunitinib Study. | completed | N/A | 223 | PfizerINDUSTRY | 17 | Jun 27, 2019 | clinicaltrials |
| NCT02390934 | Efficacy of Radium 223 in Radioactive Iodine Refractory Bone Metastases From Differentiated Thyroid Cancer(RAD-THYR) | completed | Phase 2 | 13 | Gustave Roussy, Cancer Campus, Grand ParisOTHER | 1 | Jun 11, 2019 | clinicaltrials |
| NCT02586350 | Study of Anlotinib in Patients With Medullary Thyroid Carcinoma(ALTER01031) | completed | Phase 2 / Phase 3 | 91 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | May 21, 2019 | clinicaltrials |
| NCT01089335 | Sentinel Lymphnode in Patients With Papillary Thyroid Carcinoma and in Patients With Suspected Thyroid Neoplasia(SNTC) | completed | — | 100 | Region SkaneOTHER | 1 | Mar 28, 2019 | clinicaltrials |
| NCT03024151 | The Effects of T4 Versus T4/T3 on Psychological Distress After Total Thyroidectomy in Thyroid Cancer Patients | completed | N/A | 150 | Inje UniversityOTHER | 1 | Feb 22, 2019 | clinicaltrials |
| NCT00104871 | Bortezomib in Treating Patients With Metastatic Thyroid Cancer That Did Not Respond to Radioactive Iodine Therapy | completed | Phase 2 | 24 | National Cancer Institute (NCI)NIH | 1 | Dec 19, 2018 | clinicaltrials |
| NCT00085293 | Decitabine in Treating Patients With Metastatic Papillary Thyroid Cancer or Follicular Thyroid Cancer Unresponsive to Iodine I 131 | completed | Phase 2 | 12 | National Cancer Institute (NCI)NIH | 1 | Nov 29, 2018 | clinicaltrials |
| NCT00181168 | Recombinant Thyrotropin PET-CT Fusion Scanning in Thyroid Cancer | completed | Phase 2 | 63 | Johns Hopkins UniversityOTHER | 2 | Nov 2, 2018 | clinicaltrials |
| NCT00896454 | Study of Denosumab in the Treatment of Hypercalcemia of Malignancy in Subjects With Elevated Serum Calcium | completed | Phase 2 | 33 | AmgenINDUSTRY | 5 | Oct 17, 2018 | clinicaltrials |
| NCT01438554 | Phase 1 Study of Pazopanib With GSK1120212 in Advanced Solid Tumors, Enriched With Patients With Differentiated Thyroid Cancer, Soft-tissue Sarcoma, and Cholangiocarcinoma | completed | Phase 1 | 89 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Aug 29, 2018 | clinicaltrials |
| NCT01025453 | Combination of Temsirolimus and Sorafenib in the Treatment of Radioactive Iodine Refractory Thyroid Cancer | completed | Phase 2 | 37 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Aug 15, 2018 | clinicaltrials |
| NCT03623516 | Overdiagnosis of Thyroid Cancer in the Marne and Ardennes Departments of France From 1975 to 2014(OTCancer) | completed | — | 2,008 | CHU de ReimsOTHER | 1 | Aug 9, 2018 | clinicaltrials |
| NCT01502410 | Sorafenib Tosylate in Treating Younger Patients With Relapsed or Refractory Rhabdomyosarcoma, Wilms Tumor, Liver Cancer, or Thyroid Cancer | completed | Phase 2 | 20 | National Cancer Institute (NCI)NIH | 3 | Jun 26, 2018 | clinicaltrials |
| NCT02465424 | Assessing Quality of Life Tools in Medullary Thyroid Cancer Patients(QaLM) | completed | — | 173 | Velindre NHS TrustOTHER_GOV | 1 | May 22, 2018 | clinicaltrials |
| NCT00098345 | Efficacy and Tolerability of ZD6474 in Patients With Thyroid Cancer | completed | Phase 2 | 40 | Genzyme, a Sanofi CompanyINDUSTRY | 2 | May 7, 2018 | clinicaltrials |
| NCT01424878 | Study of Molecular Pathways in Medullary Thyroid Carcinoma and Correlation of Molecular Data With Clinical Behavior of the MTC in Individuals Patients | completed | — | 150 | National Cancer Institute (NCI)NIH | 1 | Apr 5, 2018 | clinicaltrials |
| NCT01811212 | Cabozantinib-S-Malate in Treating Patients With Refractory Thyroid Cancer | completed | Phase 2 | 25 | National Cancer Institute (NCI)NIH | 1 | Apr 3, 2018 | clinicaltrials |
| NCT03363347 | BRAF V600E and Redifferentiation Therapy in Radioiodine-refractory Papillary Thyroid Cancer | completed | — | 25 | Heidelberg UniversityOTHER | 0 | Dec 6, 2017 | clinicaltrials |
| NCT03359668 | CT Detection of Metastatic Lymphadenopathy in Papillary Thyroid Cancer | completed | N/A | 47 | University Health Network, TorontoOTHER | 0 | Dec 2, 2017 | clinicaltrials |
| NCT02758158 | Tri-modal Imaging Instrument for Thyroid Cancer | completed | N/A | 9 | University Health Network, TorontoOTHER | 1 | Oct 19, 2017 | clinicaltrials |
| NCT02456701 | Enhancing Radioiodine Incorporation Into BRAF Mutant Thyroid Cancers With the Combination of Vemurafenib and KTN3379 | completed | Phase 1 | 7 | Celldex TherapeuticsINDUSTRY | 1 | Sep 5, 2017 | clinicaltrials |
| NCT03239769 | Compare the Aesthetic Effect of Different Thyroidectomies | completed | N/A | 120 | Peking University Cancer Hospital & InstituteOTHER | 0 | Aug 9, 2017 | clinicaltrials |
| NCT02114658 | Sorafenib Phase II Study for Japanese Anaplastic or Medullary Thyroid Carcinoma Patients | completed | Phase 2 | 18 | BayerINDUSTRY | 1 | Aug 3, 2017 | clinicaltrials |
| NCT02561533 | Detection of BRAF Mutation on FNAB From Papillary Thyroid Carcinoma | completed | N/A | 53 | University of AarhusOTHER | 1 | Jul 14, 2017 | clinicaltrials |
| NCT02375451 | Effect of Childhood Radioiodine Therapy on Salivary Function | completed | — | 70 | Boston Children's HospitalOTHER | 1 | Jun 26, 2017 | clinicaltrials |
| NCT01392222 | Treatment Decision-Making Among Patients Diagnosed With Papillary Microcarcinoma and Their Significant Others | completed | — | 21 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jun 21, 2017 | clinicaltrials |
| NCT02442661 | Clinical Validation of a Predictive Model for the Presence of Cervical Lymph Node Metastasis in Papillary Thyroid Cancer | completed | — | 103 | University of Colorado, DenverOTHER | 1 | Jun 12, 2017 | clinicaltrials |
| NCT01927887 | Pre-Operative Nodal Staging of Thyroid Cancer Using USPIO MRI: Preliminary Study | completed | N/A | 12 | Massachusetts General HospitalOTHER | 1 | Jun 6, 2017 | clinicaltrials |
| NCT01539655 | Study in Healthy Volunteers to Assess Effect of Omeprazole and Ranitidine on the Pharmacokinetics of Vandetanib(Vandetanib) | completed | Phase 1 | 34 | SanofiINDUSTRY | 1 | May 2, 2017 | clinicaltrials |
| NCT02109250 | CAPRELSA® REGISTRY: a Belgian Registry to Evaluate the Use of Vandetanib (Caprelsa®) in Current Clinical Practice(CaprelsaReg) | completed | — | 10 | Genzyme, a Sanofi CompanyINDUSTRY | 1 | May 2, 2017 | clinicaltrials |
| NCT00519896 | Sunitinib Malate in Treating Patients With Iodine-Refractory Recurrent or Metastatic Thyroid Cancer | completed | Phase 2 | 35 | University of WashingtonOTHER | 1 | Apr 25, 2017 | clinicaltrials |
| NCT00970359 | Reacquisition of Radioactive Iodine (RAI) Uptake of RAI-Refractory Metastatic Thyroid Cancers by Pretreatment With the Selective MEK Inhibitor AZD6244 | completed | N/A | 24 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Apr 12, 2017 | clinicaltrials |
| NCT01240590 | A Phase I/II Trial of Crolibulin (EPC2407) Plus Cisplatin in Adults With Solid Tumors With a Focus on Anaplastic Thyroid Cancer (ATC) | completed | Phase 1 / Phase 2 | 27 | National Cancer Institute (NCI)NIH | 1 | Apr 10, 2017 | clinicaltrials |
| NCT00729157 | Aflibercept in Treating Patients With Recurrent and/or Metastatic Thyroid Cancer That Did Not Respond to Radioactive Iodine Therapy | completed | Phase 2 | 41 | National Cancer Institute (NCI)NIH | 1 | Mar 15, 2017 | clinicaltrials |
| NCT01534897 | Re-differentiation of Radioiodine-Refractory BRAF V600E-mutant Papillary Thyroid Carcinoma With GSK2118436 | completed | N/A | 10 | Massachusetts General HospitalOTHER | 1 | Mar 15, 2017 | clinicaltrials |
| NCT00118248 | Tanespimycin in Treating Patients With Inoperable Locoregionally Advanced or Metastatic Thyroid Cancer | completed | Phase 2 | 41 | National Cancer Institute (NCI)NIH | 1 | Feb 15, 2017 | clinicaltrials |
| NCT00358956 | A Study To Assess ZD6474 (ZACTIMA™) Monotherapy In Locally Advanced or Metastatic Hereditary Medullary Thyroid Cancer | completed | Phase 2 | 19 | Genzyme, a Sanofi CompanyINDUSTRY | 8 | Jan 30, 2017 | clinicaltrials |
| NCT00559949 | Selumetinib in Treating Patients With Papillary Thyroid Cancer That Did Not Respond to Radioactive Iodine | completed | Phase 2 | 39 | National Cancer Institute (NCI)NIH | 2 | Jan 30, 2017 | clinicaltrials |
| NCT01083550 | Decision Making on Radioactive Iodine Treatment for Papillary Thyroid Cancer | completed | Phase 2 / Phase 3 | 74 | University Health Network, TorontoOTHER | 1 | Nov 29, 2016 | clinicaltrials |
| NCT02323724 | APPLICATION OF MOLECULAR TECHNIQUES FOR IMPROVING THE DIAGNOSIS AND TREATMENT OF NODULAR THYROID LESIONS. | completed | — | 25 | Corporacion Parc TauliOTHER | 1 | Sep 22, 2016 | clinicaltrials |
| NCT01757470 | Vandetanib Risk Minimisation Effectiveness | completed | — | 12 | Genzyme, a Sanofi CompanyINDUSTRY | 1 | Aug 31, 2016 | clinicaltrials |
| NCT02515084 | Comparison DW-MRI vs FDG PET/CT in the Detection of Early Recurrence of Cervical Well-differentiated Thyroid Carcinoma(THYRIRMTEP) | completed | Phase 2 | 37 | Centre Henri BecquerelOTHER | 1 | Aug 24, 2016 | clinicaltrials |
| NCT01204476 | Cixutumumab, Everolimus, and Octreotide Acetate in Treating Patients With Advanced Low to Intermediate Grade Neuroendocrine Carcinoma | completed | Phase 1 | 27 | National Cancer Institute (NCI)NIH | 1 | Jul 15, 2016 | clinicaltrials |
| NCT01155258 | Temsirolimus and Vinorelbine Ditartrate in Treating Patients With Unresectable or Metastatic Solid Tumors | completed | Phase 1 | 19 | University of Southern CaliforniaOTHER | 1 | Jun 13, 2016 | clinicaltrials |
| NCT01625520 | SOM230 Alone or in Combination With RAD001 in Patients With Medullary Thyroid Cancer | completed | Phase 2 | 19 | Federico II UniversityOTHER | 1 | Apr 25, 2016 | clinicaltrials |
Data updated 23 days agoSource updated Nov 29, 2019source: clinicaltrials